icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
 
 
 
THE IMPACT OF BROADER HEPATITIS C VIRUS TREATMENT STRATEGIES ON POPULATION HEALTH AND SOCIAL VALUE IN ENGLAND
 
 
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
 
Karen Van Nuys, PhD1 ⋅ Jacquelyn W. Chou, MPP, MPL1 ⋅ Alison R. Silverstein, MPH1 ⋅ Ronald Brookmeyer, PhD2 ⋅ Dana Goldman, PhD3 1Precision Health Economics, Los Angeles, CA, USA. 2. University of California, Los Angeles, CA, USA. 3. University of Southern California, Los Angeles, CA, USA.
 

0602171

Limiting HCV treatment to those with severe liver damage has no impact on reducing the incident population of HCV over time. This approach lowers treatment costs but generates fewer health benefits, higher medical expenditures, and lower productivity. In the long term, broader HCV treatment in England would lead to 7.8 billion in greater social value from more QALYs, lower medical expenditures, and increased productivity, likely due to treating active disease transmitters at an earlier disease stage, reducing the incident population over time. Strategies that tie reimbursement to long-term benefits while providing expanded access should be explored, as they have the potential to create significant value.

0602172

0602173

0602174

0602175

0602176